- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01693432
Docetaxel and S-1 for Advanced Esophageal Cancer
A Phase II Study of Docetaxel and S-1 as First-line Chemotherapy in Patients With Advanced Esophageal Cancer
Study Overview
Detailed Description
Esophageal cancer is the ninth most common cancer in male population in Korea. It was estimated that 1,864 new cases of esophageal cancer were reported and 1,434 deaths occurred in Korea in 2005.
Although half of the patients with esophageal cancer initially present with locoregional disease amenable to radical surgery or radiation-based therapy, most patients eventually develop metastatic disease with or without local recurrence.
Chemotherapy plays a major role in palliative therapy and remains to be the primary mode of treatment for the recurrent or metastatic esophageal cancer. Although various chemotherapy regimens are available, esophageal cancer carries a very poor prognosis, with a mean survival time of less than 8.1 months with current chemotherapies used singly or in combination with 5-fluorouracil (5-FU), vindesine, mitomycin, docetaxel, paclitaxel, cisplatin, irinotecan, vinorelbine, or capecitabine. The majority of the trials performed were in small numbers of patients with reported response rates from 15 to 40%.
The response was usually of short duration and there was no survival benefit with single agent chemotherapy. Combination chemotherapy has slightly improved the results in terms of duration of response (3-6 months), but still there was little improvement in overall survival. Therefore, the identification of new active agents is essential to prolong the survival.
Clinical trials of single agent docetaxel have been reported in patients with esophageal cancer and the response rate is about 18-25%.
S-1, a new biochemical modulator of 5-FU, is an oral dihydropyrimidine dehydrogenase(DPD) inhibitory fluoropyrimidine. The advantages of S-1 compared with 5-FU are greater convenience because of its oral formulation and continuous delivery, without intravenous infusion. S-1 is frequently used as a substitute for 5-FU in gastric cancer, but limited data is available for esophageal cancer.
The combination of docetaxel and S-1 is highly active and well tolerated in advanced or recurrent gastric cancer, and the synergistic antitumor activity has been fully elucidated.
Therefore, we will evaluate the efficacy of docetaxel and S-1 combination chemotherapy in Korean patients with esophageal cancer.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dae Young Zang, MD, PhD
- Phone Number: 82313803871
- Email: fhdzang@hallym.or.kr
Study Contact Backup
- Name: Jin Hee Jung, RN
- Phone Number: 82313803704
- Email: jhjung23@daum.net
Study Locations
-
-
-
Anyang, Korea, Republic of
- Recruiting
- Hallym University Medical Center
-
Contact:
- Dae Young Zang, MD, PhD
- Phone Number: 82313803871
- Email: fhdzang@hallym.or.kr
-
Contact:
- Jin Hee Jung, RN
- Phone Number: 82313803704
- Email: jhjung23@daum.net
-
Sub-Investigator:
- Hyeong Su Kim, MD
-
Sub-Investigator:
- Boram Han, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed squamous cell carcinoma or adenocarcinoma of esophagus.
- Unresectable locally advanced, recurrent or metastatic disease.
- Measurable or evaluable disease by RECIST criteria 1.1.
- Minimum age of 18 years.
- ECOG Performance status 0-2.
- Prior chemotherapy is not allowed.
- More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions are outside the radiation field)
- Adequate organ functions
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital
Exclusion Criteria:
- Other tumor type than squamous cell carcinoma and adenocarcinoma
- Previous history of chemotherapy except neoadjuvant or adjuvant chemotherapy without docetaxel and S-1
- Obvious bowel obstruction unrelieved by proper management
- Evidence of serious gastrointestinal bleeding
- Patients with CNS metastases
- Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding
- Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix
- Known history of cerebral or leptomeningeal metastases or neurologic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DS (docetaxel+S-1)
Treatment will be delivered as a 3-week cycle.
|
Treatment will be delivered as a 3-week cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: 1.5 years
|
Objective response rate will be measured from the rate of complete response (disappearance of disease) and partial response (decrease at least 30% in the sum of the longest diameters of target lesions) by RECIST (response evaluation criteria in solid tumors) guidelines.
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 1.5 years
|
Progression free survival time will be measured from the start of study treatment until documented tumor progression, or death due to any cause
|
1.5 years
|
Overall survival
Time Frame: 1.5 years
|
Overall survival time will be measured from the start of study treatment until death due to any cause
|
1.5 years
|
Toxicity profiles
Time Frame: 1.5 years
|
adverse events will be descripted and graded using NCI-CTCAE version 4.0
|
1.5 years
|
Disease control rate
Time Frame: 1.5 years
|
Disease control rate will be measured from the rate of complete response (disappearance of disease), partial response (decrease at least 30% in the sum of the longest diameters of target lesions), and stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) by RECIST (response evaluation criteria in solid tumors) guidelines.
|
1.5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
Other Study ID Numbers
- HMC-HO-GI-1202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal AdenocarcinomaUnited States
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
University of Michigan Rogel Cancer CenterGenentech, Inc.TerminatedLoco-regional Esophageal Cancer
-
Universitaire Ziekenhuizen KU LeuvenCompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)Belgium
-
Emory UniversityNovartisCompletedEsophageal Cancer | Neoplasms, EsophagealUnited States
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & InstituteRecruitingEsophageal Neoplasm Metastatic | Esophageal Cancer Stage IVbChina
-
Biotech Pharmaceutical Co., Ltd.Completed
Clinical Trials on DS (docetaxel+S-1)
-
Yonsei UniversityUnknownGastric AdenocarcinomaKorea, Republic of
-
Japan Clinical Cancer Research OrganizationKorean Cancer Study GroupCompleted
-
Hospital Universitari de BellvitgeCompletedMorbid Obesity | Bariatric SurgerySpain
-
McGill University Health Centre/Research Institute...Active, not recruitingSingle Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): A Prospective Cohort StudyObesity | Morbid ObesityCanada
-
Biotronik SE & Co. KGCompletedHeart Failure | TachyarrhythmiaNetherlands, Switzerland, Latvia, Germany, Austria, Hungary, Slovakia
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaTerminatedHead and Neck Squamous Cell CarcinomaKorea, Republic of
-
Chonnam National University HospitalChungbuk National University; Chungnam National University; Chonbuk National...CompletedHead and Neck CancerKorea, Republic of
-
National Cancer Center, KoreaCompletedStomach NeoplasmsKorea, Republic of
-
National Cancer Center, KoreaUnknownStomach NeoplasmsKorea, Republic of